Risk of Cancer-Specific Death May Remain Elevated for 30 Years
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
Prostate Cancer
PSA Screening for Prostate Cancer Beneficial, Especially for Black Men
In all studied scenarios, PSA screening appeared more favorable for Black men than for the general population.
Active Surveillance Rate for Low-Risk Prostate Cancer Is Rising
Although most men with low-risk prostate cancer are now managed initially with active surveillance, use of this approach remains suboptimal, according to investigators.
Study: Confirmatory Prostate Biopsies Still Needed Despite Upfront MRI
New findings challenge recommendations from the European Association of Urology.
Prostate Cancer Upgrading on AS Linked to Perineural Invasion
The presence of perineural invasion in a prostate biopsy has important implications for active surveillance.
Prostate Cancer Upgrading Risk in Active Surveillance Does Not Differ by Race
Active surveillance appears to be a safe treatment option for low- and very low-risk prostate cancer, regardless of race, according to investigators.
Negative MRI in Active Surveillance Often Predicts Stable Prostate Cancer
Some patients with a negative mpMRI while on prostate cancer active surveillance may be able to defer biopsy, according to investigators.
PSA Bounce vs Biochemical Recurrence After Prostate Cancer SBRT Probed
Study reveals factors that could distinguish PSA bounce from biochemical recurrence after stereotactic body radiation therapy for prostate cancer.
Prostate Cancer Grade Migration Documented
Grade group 1 prostate cancers declined as a proportion of all prostate cancers.
Metastatic Prostate Cancer Survival Improved in Wake of Treatment Advances
Following the approval of cabazitaxel in 2010, there are now an unprecedented number of life-prolonging therapies for men with metastatic disease.
- Loading...
Loading...
Next post in AUA 2022 Annual Meeting
Loading... 
Loading...